ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and ...

It also relates to the early stage givosiran for acute hepatic porphyrias, Silence Therapeutics said. There is no suggestion that Alnylam and The Medicines Company acquired intellectual property ...

The FDA has approved the first ever RNA interference drug – Alnylam’s Onpattro (patisiran) for the nerve damage caused by the rare disease hereditary transthyretin-mediated amyloidosis (hATTR ...

Then, there is givosiran, which was approved a year later, to treat a condition called acute hepatic porphyria, a rare genetic disease that causes severe abdominal pain and other symptoms. As it is ...